Smita shewale biography of abraham

  • Thank you for living life to the fullest, Mary, for being an enormous inspiration and for opening doors for all women in the motorsports world.
  • Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine.
  • In this episode, famous Marathi actress Smita Shewale has interviewed Dr. Abraham and Isaac, to thee I will give it, and to thy seed.

    • •

    Wikipedia:WikiProject Women in Red/Missing articles by nationality/India

    name image description occupation date of birth date of death place of birth place of death wikidata item site links Nalinibala Bhanja ChoudhuraniBengali writer writerNo/unknown value No/unknown value Q285330841 Swagata Sen PillaiIndian Bharatnatyam dancer writer
    dancerNo/unknown value Q312011711 Basantakumari DasiBengali writer writerNo/unknown value No/unknown value Q331337611 Binay Kumari BoseBengali writer writer1872 No/unknown value Q331880111 Annadasundari GhoshBengali poet (1873-1950) poet
    writer1873-12-31 1950-07-20 Q332488612 Shireen JinnahPakistani writer politician1880 1980-12-02 Mumbai
    British RajKarachiQ74985361 Fulla NayakIndian supercentenarian 19th century 2006-11-19 Q156598563 Evelyn Grace InceBritish painter painter
    artist1886 1941 Q214590390
  • smita shewale biography of abraham

    • •

    Abstract

    Introduction: Maharashtra, India, remained a hotspot during the COVID-19 pandemic. After the initial complete lockdown, the state slowly relaxed restrictions. We aim to estimate the lockdown’s impact on COVID-19 cases and associated healthcare costs. Methods: Using daily case data for 84 days (9 March–31 May 2020), we modeled the epidemic’s trajectory and predicted new cases for different phases of lockdown. We fitted log-linear models to estimate the growth rate, basic (R0), daily reproduction number (Re), and case doubling time. Based on pre-restriction and Phase 1 R0, we predicted new cases for the rest of the restriction phases, and we compared them with the actual number of cases during each phase. Furthermore, using the published and gray literature, we estimated the costs and savings of implementing these restrictions for the projected period, and we performed a sensitivity analysis. Results: The estimated median R0 during the different phases was 1.14 (95%

    •

    Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial

    Background: To meet global cervical cancer elimination efforts, a wider range of affordable and accessible vaccines against human papillomavirus (HPV) are needed. We aimed to evaluate the immunogenicity and safety of a quadrivalent HPV vaccine (targeting HPV types 6, 11, 16, and 18), developed and manufactured by the Serum Institute of India (SIIPL). Here we report outcomes in the 9-14 years cohort.

    Methods: This randomised, active-controlled, phase 2/3 trial was conducted at 12 tertiary care hospitals across India. Healthy participants aged 9-14 years or 15-26 years with no history of HPV vaccination were eligible for enrolment. Female participants were randomly assigned (1:1) with an interactive web response system, by use of a centr